Design analysis of a high resolution detector block for a low cost small animal positron emission imaging system

Author(s):  
R.S. Miyaoka ◽  
T.K. Lewellen
1988 ◽  
Vol 8 (2) ◽  
pp. 171-179 ◽  
Author(s):  
M. Martin ◽  
C. Lemaire ◽  
W. G. Tatton ◽  
R. L. Armstrong ◽  
R. Struk

2012 ◽  
Vol 246-247 ◽  
pp. 213-218
Author(s):  
Chun Liang ◽  
Jian Xin Shen ◽  
Sai Sai Niu

Ocular retinal imaging is a major diagnostic modality for retinal disease, and can play a critical role for diagnosing systemic diseases such as diabetes and eye-specific diseases such as macular degeneration and diabetic retinopathy, the leading causes of blindness. In order to get high-resolution retinal imaging and develop the low-cost and compact retinal imaging system, we employ micro adaptive optics, which is consisted of wavefront sensor, wavefront corrector and control system. In this paper, the theory, design and testing of the ocular retinal microscopy is detailed, with an emphasis on the eye wavefront aberration describing, aberration detecting method with Hartmann-Shack wavefront sensing and close-loop aberration compensating by micromachined membrane deformable mirrors(MMDM).The ocular retinal microscopy experimental setup is built, the retinal cell imaging had been snapped. It is showed in this work that the ocular retinal microscopy based on adaptive optics system can enable diffraction-limited imaging of micro-scale features of the retina, through real-time compensation of aberrations introduced by the eye.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kevin P. Labadie ◽  
Andrew D. Ludwig ◽  
Adrienne L. Lehnert ◽  
Donald K. Hamlin ◽  
Aimee L. Kenoyer ◽  
...  

AbstractGlypican-3 (GPC3) is a tumor associated antigen expressed by hepatocellular carcinoma (HCC) cells. This preclinical study evaluated the efficacy of a theranostic platform using a GPC3-targeting antibody αGPC3 conjugated to zirconium-89 (89Zr) and yttrium-90 (90Y) to identify, treat, and assess treatment response in a murine model of HCC. A murine orthotopic xenograft model of HCC was generated. Animals were injected with 89Zr-labeled αGPC3 and imaged with a small-animal positron emission/computerized tomography (PET/CT) imaging system (immuno-PET) before and 30 days after radioimmunotherapy (RIT) with 90Y-labeled αGPC3. Serum alpha fetoprotein (AFP), a marker of tumor burden, was measured. Gross tumor volume (GTV) and SUVmax by immuno-PET was measured using fixed intensity threshold and manual segmentation methods. Immuno-PET GTV measurements reliably quantified tumor burden prior to RIT, strongly correlating with serum AFP (R2 = 0.90). Serum AFP was significantly lower 30 days after RIT in 90Y-αGPC3 treated animals compared to those untreated (p = 0.01) or treated with non-radiolabeled αGPC3 (p = 0.02). Immuno-PET GTV measurements strongly correlated with tumor burden after RIT (R2 = 0.87), and GTV of animals treated with 90Y-αGPC3 was lower than in animals who did not receive treatment or were treated with non-radiolabeled αGPC3, although this only trended toward statistical significance. A theranostic platform utilizing GPC3 targeted 89Zr and 90Y effectively imaged, treated, and assessed response after radioimmunotherapy in a GPC3-expressing HCC xenograft model.


Sign in / Sign up

Export Citation Format

Share Document